Known targets — ChEMBL curated mechanism
DHFRGARTPTGFRPTGIRPTGS1PTGS2TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8envmurAthyA
The experimentally established mechanism targets of Etiproston. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGFR known ✓ | P43088 | 13/20 | 0.60 |
| ▸ | PTGER3 | P43115 | 6/20 | 0.60 |
| ▸ | TBXA2R | P21731 | 5/20 | 0.60 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.43 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.43 |
| ▸ | SLCO2A1 | Q92959 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Etiproston SCHEMBL11602088 | 0.94 | PTGFR (0.67) | PTGFRPTGER3TBXA2RPTGER1LMNA | |
| Etiproston SCHEMBL11603831 | 0.94 | PTGFR (0.67) | PTGFRPTGER3TBXA2RPTGER1LMNA | |
| Etiproston SCHEMBL12495605 | 0.94 | PTGFR (0.67) | PTGFRPTGER3TBXA2RPTGER1LMNA | |
| Etiproston SCHEMBL11602481 | 0.94 | PTGFR (0.67) | PTGFRPTGER3TBXA2RPTGER1LMNA | |
| Etiproston SCHEMBL571117 | 0.94 | PTGFR (0.67) | PTGFRPTGER3TBXA2RPTGER1LMNA | |
| Etiproston SCHEMBL12495609 | 0.94 | PTGFR (0.67) | PTGFRPTGER3TBXA2RPTGER1LMNA | |
| SCHEMBL11602425 | 0.86 | PTGFR (0.57) | PTGFRPTGER3TBXA2RPTGER1LMNA | |
| SCHEMBL11602885 | 0.86 | PTGFR (0.57) | PTGFRPTGER3TBXA2RPTGER1LMNA | |
| SCHEMBL11601015 | 0.86 | PTGFR (0.57) | PTGFRPTGER3TBXA2RPTGER1LMNA | |
| SCHEMBL11602179 | 0.86 | PTGFR (0.57) | PTGFRPTGER3TBXA2RPTGER1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6683071-B1 | SUPPLYING A PROSTAGLANDIN POST PARTUM THEN TREATING WITH A PROGESTERONE | THE UNIVERSITY OF NOTTINGHAM (GB) | 2004-01-27 | — | — | US | claimed |
| WO-2001017512-A2 | COMBINATION PREPARATION FOR INITIATION OF OESTRUS | MILK DEVELOPMENT COUNCIL (GB) | 2001-03-15 | — | — | WO | claimed |
| US-20140234271-A1 | COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS | THE HOSPITAL FOR SICK CHILDREN (CA) | 2014-08-21 | — | — | US | disclosed |
| US-8748177-B2 | Compositions for proliferation of cells and related methods | THE HOSPITAL FOR SICK CHILDREN (CA) | 2014-06-10 | — | — | US | disclosed |
| EP-2598150-A2 | COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS | The Hospital For Sick Children (CA) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012018643-A2 | COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS | THE HOSPITAL FOR SICK CHILDREN (CA) | 2012-02-09 | — | — | WO | disclosed |
| US-20110301105-A1 | COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS | THE HOSPITAL FOR SICK CHILDREN (CA) | 2011-12-08 | — | — | US | disclosed |
| WO-2010039679-A1 | COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS | THE HOSPITAL FOR SICK CHILDREN (CA) | 2010-04-08 | — | — | WO | disclosed |
| WO-2001017512-A2 | COMBINATION PREPARATION FOR INITIATION OF OESTRUS | MILK DEVELOPMENT COUNCIL (GB) | 2001-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140234271-A1 | COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS | MKI67, KRT18, PROX1 | PTGFR 3229/4885PTGER3 4290/4885TBXA2R 4777/4885 |
| US-20110301105-A1 | COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS | MKI67, KRT18, PROX1 | PTGFR 3229/4885PTGER3 4290/4885TBXA2R 4777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.